CN111587109A - 用于治疗神经肌肉病症的苯氧酸 - Google Patents

用于治疗神经肌肉病症的苯氧酸 Download PDF

Info

Publication number
CN111587109A
CN111587109A CN201880080205.1A CN201880080205A CN111587109A CN 111587109 A CN111587109 A CN 111587109A CN 201880080205 A CN201880080205 A CN 201880080205A CN 111587109 A CN111587109 A CN 111587109A
Authority
CN
China
Prior art keywords
acid
optionally substituted
deuterium
different substituents
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880080205.1A
Other languages
English (en)
Chinese (zh)
Inventor
T·霍尔姆彼得森
L·J.S.克努森
N·凯利
M·布洛克-利普斯
C·埃尔斯伯格奥勒森
M·拉贝尔
O·贝卡德尼尔森
R·库马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NMD Pharma AS
Original Assignee
NMD Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NMD Pharma AS filed Critical NMD Pharma AS
Publication of CN111587109A publication Critical patent/CN111587109A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/14—Acetic acid esters of monohydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201880080205.1A 2017-12-14 2018-12-14 用于治疗神经肌肉病症的苯氧酸 Pending CN111587109A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598940P 2017-12-14 2017-12-14
US62/598,940 2017-12-14
EP18151605 2018-01-15
EP18151605.5 2018-01-15
PCT/EP2018/084980 WO2019115777A1 (en) 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders

Publications (1)

Publication Number Publication Date
CN111587109A true CN111587109A (zh) 2020-08-25

Family

ID=64661403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880080205.1A Pending CN111587109A (zh) 2017-12-14 2018-12-14 用于治疗神经肌肉病症的苯氧酸

Country Status (12)

Country Link
EP (1) EP3723745B1 (https=)
JP (1) JP2021506813A (https=)
KR (1) KR20200099146A (https=)
CN (1) CN111587109A (https=)
AU (1) AU2018382597B2 (https=)
CA (1) CA3085226A1 (https=)
IL (1) IL274744B2 (https=)
MX (1) MX2020005398A (https=)
SG (1) SG11202005359TA (https=)
TW (1) TWI794369B (https=)
WO (1) WO2019115777A1 (https=)
ZA (1) ZA202002936B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025637A2 (pt) * 2019-06-19 2022-02-01 Nmd Pharma As Compostos para o tratamento de doenças neuromusculares
WO2024121130A1 (en) 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2024121129A1 (en) * 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
EP4731200A1 (en) 2023-06-20 2026-04-29 NMD Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases
WO2025196206A1 (en) 2024-03-20 2025-09-25 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662484A (zh) * 2002-06-26 2005-08-31 韩国化学研究院 制备(r)芳氧基丙酸酯衍生物的方法
CN101983061A (zh) * 2008-02-04 2011-03-02 赛特凯恩蒂克公司 某种化学物质、组合物和方法
WO2016202341A1 (en) * 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
TW201720437A (zh) * 2015-10-29 2017-06-16 東北泰克諾亞奇股份有限公司 肌萎縮性疾病治療劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1586463A (en) 1976-08-02 1981-03-18 Shell Int Research Herbicidal compositions
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662484A (zh) * 2002-06-26 2005-08-31 韩国化学研究院 制备(r)芳氧基丙酸酯衍生物的方法
CN101983061A (zh) * 2008-02-04 2011-03-02 赛特凯恩蒂克公司 某种化学物质、组合物和方法
WO2016202341A1 (en) * 2015-06-15 2016-12-22 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
TW201720437A (zh) * 2015-10-29 2017-06-16 東北泰克諾亞奇股份有限公司 肌萎縮性疾病治療劑

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIUSEPPE FRACCHIOLLA等: "Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxyacetic Acid Analogues with PPARa and PPARg Agonist Activity", 《CHEM MED CHEM》 *
MARIA GRAZIA PERRONE等: "Reaction of caesium 4-chlorophenate and chlorohydrins from threonines: synthesis of clofibrate analogues", 《TETRAHEDRON: ASYMMETRY》 *
MICHAEL等: "Pharmacological Characterization of Chloride Channels Belonging to the ClC Family by the Use of Chiral Clofibric Acid Derivatives", 《MOL PHARMACOL》 *

Also Published As

Publication number Publication date
KR20200099146A (ko) 2020-08-21
IL274744B2 (en) 2023-02-01
IL274744B (en) 2022-10-01
TWI794369B (zh) 2023-03-01
EP3723745B1 (en) 2024-06-19
SG11202005359TA (en) 2020-07-29
CA3085226A1 (en) 2019-06-20
AU2018382597A1 (en) 2020-07-02
EP3723745A1 (en) 2020-10-21
ZA202002936B (en) 2024-11-27
JP2021506813A (ja) 2021-02-22
IL274744A (en) 2020-07-30
MX2020005398A (es) 2020-08-17
AU2018382597B2 (en) 2024-04-04
TW201938525A (zh) 2019-10-01
EP3723745C0 (en) 2024-06-19
WO2019115777A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
CN111587109A (zh) 用于治疗神经肌肉病症的苯氧酸
EP3307262B1 (en) Compounds for use in treating neuromuscular disorders
CN111712489B (zh) 用于治疗神经肌肉病症的化合物
ES2911895T3 (es) Fenoxiácidos para el tratamiento de trastornos neuromusculares
US12168643B2 (en) Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) Compounds for the treatment of neuromuscular disorders
US12415771B2 (en) Compounds for the treatment of neuromuscular disorders
US20260007625A1 (en) Compounds for the Treatment of Neuromuscular Disorders
US11147788B2 (en) Compounds for the treatment of neuromuscular disorders
US20190183812A1 (en) Compounds For The Treatment Of Neuromuscular Disorders
US11591284B2 (en) Compounds for the treatment of neuromuscular disorders
HK40068705B (en) Compounds for the treatment of neuromuscular disorders
HK40068705A (en) Compounds for the treatment of neuromuscular disorders
HK40029101A (en) Compounds for the treatment of neuromuscular disorders
HK40029101B (en) Compounds for the treatment of neuromuscular disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200825